Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Nicolaas Schaap"'
Autor:
Gloria Tridello, Didier Blaise, Patrice Chevallier, Grzegorz W. Basak, Eric Deconinck, Jan Styczyński, Nicolaus Kröger, Diana Averbuch, Ibrahim Yakoub-Agha, Silvia Montoto, Nicolaas Schaap, Edouard Forcade, Rafael de la Cámara, Nina Knelange, Stephanie Nguyen-Quoc, Jakob Passweg, Catherine Cordonnier, Lidia Gil, Jan J. Cornelissen, Mauricette Michallet, Simone Cesaro, Katherine N. Ward, Nigel H. Russell, Gérard Socié, Eefke Petersen, Per Ljungman, Hendrik Veelken, Nathalie Fegueux, Peter Bader, Malgorzata Mikulska, Johan Maertens
Publikováno v:
Bone Marrow Transplantation, 54(12), 2060-2071. Nature Publishing Group
Bone Marrow Transplantation, 54(12), 2060-2071. NATURE PUBLISHING GROUP
Bone Marrow Transplantation, 54, 12, pp. 2060-2071
Bone Marrow Transplantation, 54, 2060-2071
Bone Marrow Transplantation, 54(12), 2060-2071. NATURE PUBLISHING GROUP
Bone Marrow Transplantation, 54, 12, pp. 2060-2071
Bone Marrow Transplantation, 54, 2060-2071
The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients
Autor:
Paolo Bartolomeo, Tsila Zuckerman, Liisa Volin, Peter Brossart, Yener Koc, Donal P. McLornan, Jakob Passweg, Per Ljungman, Nicolaus Kröger, Dominik Wolf, Liesbeth C. de Wreede, Fabio Ciceri, Stefania Bregante, Kavita Raj, Kristina Carlson, Ibrahim Yakoub-Agha, Didier Blaise, Antonin Vitek, Eduardo Olavarria, Henric Jan Blok, José Luis Díez-Martín, Marie Robin, Nicolaas Schaap, Yves Chalandon, Diderik Jan Eikema
Publikováno v:
Biology of Blood and Marrow Transplantation, 25(3), 522-528
Biology of Blood and Marrow Transplantation, 25, 3, pp. 522-528
Biology of Blood and Marrow Transplantation, 25, 522-528
Biology of Blood and Marrow Transplantation, 25, 3, pp. 522-528
Biology of Blood and Marrow Transplantation, 25, 522-528
Contains fulltext : 202803.pdf (Publisher’s version ) (Open Access) This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transpla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c769b114d2794b9899ab8977d6a0c289
http://hdl.handle.net/1887/121452
http://hdl.handle.net/1887/121452
Autor:
Rebecca Wijers, Cor H. J. Lamers, Eefke Petersen, Burak Kalin, Nicolaas Schaap, Mariëtte N. D. Ter Borg, Eric Braakman, Cornelis A.M. van Bergen, Jan J. Cornelissen, J.H. Frederik Falkenburg, Sacha Zeerleder, Annoek E.C. Broers, Bronno van der Holt, Judith A.E. Somers, Jürgen Kuball, Ellen Meijer
Publikováno v:
HemaSphere, 3(5)
HemaSphere
HemaSphere, 3(5):e285. Wolters Kluwer Health
HemaSphere, 3(5):UNSP e285. Wolters Kluwer Health
HemaSphere, Vol 3, Iss 5 (2019)
Kalin, B, Ter Borg, M, Wijers, R, Somers, J A E, Van Der Holt, B, Van Bergen, C A M, Petersen, E J, Kuball, J, Meijer, E, Schaap, N P M, Zeerleder, S S, Broers, A E, Braakman, E, Frederik Falkenburg, J H, Lamers, C H J & Cornelissen, J J 2019, ' Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients : A Phase II Study Focusing on the Mechanism of Graft Predominance ', HemaSphere, vol. 3, no. 5, e285 . https://doi.org/10.1097/HS9.0000000000000285
HemaSphere
HemaSphere, 3(5):e285. Wolters Kluwer Health
HemaSphere, 3(5):UNSP e285. Wolters Kluwer Health
HemaSphere, Vol 3, Iss 5 (2019)
Kalin, B, Ter Borg, M, Wijers, R, Somers, J A E, Van Der Holt, B, Van Bergen, C A M, Petersen, E J, Kuball, J, Meijer, E, Schaap, N P M, Zeerleder, S S, Broers, A E, Braakman, E, Frederik Falkenburg, J H, Lamers, C H J & Cornelissen, J J 2019, ' Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients : A Phase II Study Focusing on the Mechanism of Graft Predominance ', HemaSphere, vol. 3, no. 5, e285 . https://doi.org/10.1097/HS9.0000000000000285
Autor:
Francesco Passamonti, Moshe Talpaz, Ruben A. Mesa, Derek Tang, Alessandro M. Vannucchi, Sonja Zweegman, Jean-Jacques Kiladjian, Nicolaas Schaap, Jun Zhang, Claire N. Harrison, Peiwen Yu, John Mascarenhas, Xiaomei Ye, Srdan Verstovsek, Shelonitda Rose
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S328
Context: MF is characterized by anemia, progressive splenomegaly, and debilitating constitutional symptoms. Fedratinib is a selective JAK2 inhibitor approved in the US for adult patients with intermediate-2 or high-risk MF. Fedratinib was assessed in
Autor:
Sonja Zweegman, Srdan Verstovsek, Francesco Passamonti, Jun Zhang, Nicolaas Schaap, Ruben A. Mesa, Claire N. Harrison, Alessandro M. Vannucchi, Moshe Talpaz, Shelonitda Rose, Carrie Brownstein, Tymara Berry, Jean-Jacques Kiladjian
Publikováno v:
Blood. 134:668-668
Introduction: Cytopenias are a leading cause of ruxolitinib (RUX) discontinuation for patients (pts) with myelofibrosis (MF). Though RUX 5 mg BID is recommended for pts with platelet (PLT) counts of 50 to Methods: JAKARTA and JAKARTA2 enrolled adult
Autor:
Claire N. Harrison, Mingyu Li, Srdan Verstovsek, Tymara Berry, Nicolaas Schaap, Eric Jourdan, Moshe Talpaz, Torsten Gerike, Alessandro M. Vannucchi, Richard T. Silver, Harry C. Schouten, Sonja Zweegman, Ruben A. Mesa, Jean-Jacques Kiladjian, Shelonitda Rose, Francesco Passamonti, Carrie Brownstein
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S356
Autor:
Leszek Miszczyk, Ibrahim Yakoub-Agha, Myriam Labopin, Emmanuelle Polge, Gérard Socié, Arnon Nagler, Jan J. Cornelissen, Sebastian Giebel, Gokoulakrichenane Loganadane, Norbert Claude Gorin, Mauricette Michallet, Mohamad Mohty, Yazid Belkacemi, Marrow Transplantation, Nicolaas Schaap
Publikováno v:
International Journal of Radiation Oncology, Biology, Physics, 102, 515-526
International Journal of Radiation Oncology Biology Physics, 102(3), 515-526. Elsevier Inc.
International Journal of Radiation Oncology, Biology, Physics, 102, 3, pp. 515-526
International Journal of Radiation Oncology Biology Physics, 102(3), 515-526. Elsevier Inc.
International Journal of Radiation Oncology, Biology, Physics, 102, 3, pp. 515-526
Purpose Total-body irradiation (TBI) is a major constituent of myeloablative conditioning regimens. The standard technique consists of 12 Gy in 6 fractions over a period of 3 days. The Standard-fractionation compAred to one-daily fRaction total body
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65f65c9aea76c5fccf969eae63711f51
http://hdl.handle.net/2066/195628
http://hdl.handle.net/2066/195628
Autor:
Pavel Jindra, Rik Schots, Dietrich W. Beelen, Laurent Garderet, Simona Iacobelli, Stig Lenhoff, Didier Blaise, Xavier Poiré, Arnon Nagler, Dimitris Ziagkos, Charles Craddock, Per Ljungman, Patrice Chevallier, Ibrahim Yakoub-Agha, Nicolaus Kröger, Jakob Passweg, Nicolaas Schaap, Jaime Sanz, Marie Robin, Alessandro Rambaldi, Liisa Volin, Anja van Biezen, Ghulam J. Mufti, Jürgen Finke, Johan Maertens
Publikováno v:
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (3), pp.507-513. ⟨10.1016/j.bbmt.2017.11.017⟩
Biology of Blood and Marrow Transplantation, 24, 507-513
Biology of Blood and Marrow Transplantation, 24, 3, pp. 507-513
Biology of Blood and Marrow Transplantation, Vol. 24, no.3, p. 507-513 (2018)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Biology of Blood and Marrow Transplantation, 24(3), 507-513
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (3), pp.507-513. ⟨10.1016/j.bbmt.2017.11.017⟩
Biology of Blood and Marrow Transplantation, 24, 507-513
Biology of Blood and Marrow Transplantation, 24, 3, pp. 507-513
Biology of Blood and Marrow Transplantation, Vol. 24, no.3, p. 507-513 (2018)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Biology of Blood and Marrow Transplantation, 24(3), 507-513
The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0e937b5827b0914384a5ee96ac58ad1
https://hal-amu.archives-ouvertes.fr/hal-02143674
https://hal-amu.archives-ouvertes.fr/hal-02143674
Autor:
Nicole M. A. Blijlevens, Walter J.F.M. van der Velden, Aleida M. Liefferink, Lenneke F.J. van Groningen, Anton F.J. de Haan, J. Peter Donnelly, Nicolaas Schaap
Publikováno v:
Biology of Blood and Marrow Transplantation, 22, 1, pp. 179-82
ResearcherID
Web of Science
Biology of Blood and Marrow Transplantation, 22, 179-82
ResearcherID
Web of Science
Biology of Blood and Marrow Transplantation, 22, 179-82
Item does not contain fulltext Steroid-refractory acute graft-versus-host disease (aGVHD) remains an important cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). A protocol on the management of aGVHD was introduced in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97c772e5c5d25194fc74433ebbd2eca
https://hdl.handle.net/2066/172152
https://hdl.handle.net/2066/172152
Autor:
Rianne Ammerlaan, Monique C. Minnema, Okke de Weerdt, Sonja Zweegman, Marie José Kersten, Marinus H. J. van Oers, Pieter Sonneveld, Reinier Raymakers, Nicolaas Schaap, Shulamiet Wittebol, Jan J. Cornelissen, Gerard M. J. Bos, Bronno van der Holt, Henk M. Lokhorst
Publikováno v:
Haematologica, 100(12), E508-E510. Ferrata Storti Foundation
Haematologica, 100, e508-10
Lokhorst, H M, van der Holt, B, Cornelissen, J J, Kersten, M J, van Oers, M, Raymakers, R, Minnema, M C, Zweegman, S, Bos, G, Schaap, N, Wittebol, S, de Weerdt, O, van Ammerlaan, R & Sonneveld, P 2015, ' Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival ', Haematologica, vol. 100, no. 12, pp. E508-E510 . https://doi.org/10.3324/haematol.2015.128728
Haematologica, 100(12), e508-e510. Ferrata Storti Foundation
Haematologica, 100, 12, pp. e508-10
Haematologica, 100, e508-10
Lokhorst, H M, van der Holt, B, Cornelissen, J J, Kersten, M J, van Oers, M, Raymakers, R, Minnema, M C, Zweegman, S, Bos, G, Schaap, N, Wittebol, S, de Weerdt, O, van Ammerlaan, R & Sonneveld, P 2015, ' Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival ', Haematologica, vol. 100, no. 12, pp. E508-E510 . https://doi.org/10.3324/haematol.2015.128728
Haematologica, 100(12), e508-e510. Ferrata Storti Foundation
Haematologica, 100, 12, pp. e508-10
Results of Allogeneic Stem Cell Transplantation (Allo-SCT) as part of first-line therapy for multiple myeloma (MM) are conflicting.1–7 The 96 month long-term followup of the EBMT trial showed a significantly prolonged PFS and OS for Auto-/Allo-SCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae256c3aba39f003c8994c6f593b7cc
https://research.vumc.nl/en/publications/69105eba-79a0-4058-88c2-26a140da059c
https://research.vumc.nl/en/publications/69105eba-79a0-4058-88c2-26a140da059c